Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firms behind them -- so individuals can make better investing decisions.
Anyone can also use Motley Fool CAPS to monitor the collective opinions of more than 135,000 members, many of whom demonstrate better investing insight than published analysts.
Enough top-performing CAPS members have turned bullish on Illumina
While Sequenom
Similar to how Procter & Gamble's
This helped the company pull in $38 million in free cash flow for the quarter, leaving it with a sizable hoard of $351 million in cash and equivalents and another $321 million in short-term investments.
The company's results outshone those of smaller competitor Luminex
Some investors anticipate the company will benefit from stimulus funds allocated to the NIH over the next couple of years. The company has already begun working with customers to help them acquire new grants and funding that will be available.
To see what the very best CAPS analysts are saying now about Illumina -- as well as other winning stocks they are picking -- head on over to CAPS and have a look.
More Foolishness: